CervoMed Inc.’s stock cratered early Tuesday after the biotech company said a midstage trial of a treatment for patients with dementia with Lewy bodies, or DLB, failed to meet its main goals.

On Tuesday, CervoMed Inc. (NASDAQ:CRVO) stock is trading lower after the company revealed topline data from the RewinD-LB Phase 2b clinical trial evaluating neflamapimod for dementia with Lewy ...

CervoMed was testing neflamapimod in the 159-patient trial as a treatment for a form of dementia that is caused by the accumulation of protein deposits called Lewy bodies in the brain's nerve cells.

BOSTON, Dec. 10, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ ... evaluating neflamapimod for the treatment of patients with dementia with Lewy bodies (DLB). The trial did not meet statistical ...

CervoMed’s ex-Vertex drug has failed to reduce the severity of patients’ dementia in a phase 2 trial, halting plans for a late-stage study. The drug in question is neflamapimod, a p38 MAP ...

CervoMed's RewinD-LB Phase 2b trial for neflamapimod in dementia with Lewy bodies failed to meet primary and key secondary endpoints. The trial's topline analysis revealed suboptimal plasma drug ...

(RTTNews) - CervoMed Inc. (CRVO) announced Tuesday that its RewinD-LB Phase 2b clinical trial evaluating neflamapimod in patients with dementia with Lewy bodies or DLB failed to demonstrate ...

On Tuesday, CervoMed Inc. (NASDAQ:CRVO) stock is trading lower after the company revealed topline data from the RewinD-LB Phase 2b clinical trial evaluating neflamapimod for dementia with Lewy bodies ...

About the RewinD-LB Phase 2b Trial in Dementia with Lewy Bodies CervoMed’s Phase 2b trial, RewinD-LB, is a randomized, 16-week, double-blind, placebo-controlled clinical trial evaluating oral ...